| Literature DB >> 34952950 |
Kazuo Kobayashi1,2, Keiichi Chin3, Shinichi Umezawa3, Shun Ito3, Hareaki Yamamoto3, Shiro Nakano3, Nobukazu Takada3, Nobuo Hatori4, Kouichi Tamura5.
Abstract
To prevent further spread of coronavirus disease 2019 (COVID-19), the Japanese government announced a state of emergency, resulting in major stress for the population. The aim of this study was to investigate a possible association between changes in daily stress and blood pressure (BP) in Japanese patients. We retrospectively investigated 748 patients with chronic disease who were treated by the Sagamihara Physicians Association to determine changes in stress during the COVID-19 state of emergency from 7 April to 31 May 2020. During the state of emergency, office BP significantly increased from 136.5 ± 17.5/78.2 ± 12.0 to 138.6 ± 18.6/79.0 ± 12.2 (p < 0.001 and p = 0.03, respectively). In contrast, home BP significantly decreased from 128.2 ± 10.3/75.8 ± 8.8 to 126.9 ± 10.2/75.2 ± 9.0 (p < 0.001 and p = 0.01, respectively), and the ratio of white coat hypertension was significantly increased (p < 0.001). Fifty-eight percent of patients worried about adverse effects of hypertension as a condition contributing to the severity and poor prognosis of COVID-19; decreased amounts of exercise and worsened diet compositions were observed in 39% and 17% of patients, respectively. In conclusion, a significant increase in office BP with the white coat phenomenon was observed during the state of emergency, as well as an increase in related stress. To prevent cardiovascular events, general practitioners should pay more attention to BP management during stressful global events, including the COVID-19 pandemic.Entities:
Keywords: A state of emergency; Coronavirus disease-2019; White coat hypertension
Mesh:
Year: 2021 PMID: 34952950 PMCID: PMC8705072 DOI: 10.1038/s41440-021-00832-w
Source DB: PubMed Journal: Hypertens Res ISSN: 0916-9636 Impact factor: 3.872
Clinical background of cases during the state of emergency due to COVID-19.
| Total ( | Analyzed cases | During the state of emergency |
|---|---|---|
| Male (%) | 748 | 424 (57%) |
| Age (years-old) | 748 | 67.3 ± 12.3 (range, 22–97) |
| Current smoke | 520 | 31 (6%) |
| Hypertensin | 748 | 714 (95%) |
| Diabetes mellitus | 748 | 423 (57%) |
| Dyslipidemia | 610 | 544 (89%) |
| Chronic kidney disease | 610 | 336 (55%) |
| Cardiovascular disease | 610 | 104 (17%) |
| Cerebrovascular disease | 610 | 40 (7%) |
| BMI | 519 | 24.0 ± 3.5 |
| BW (kg) | 715 | 63.9 ± 12.8 |
| Office SBP/DBP (mmHg) | 748 | 138.6 ± 18.6/ 79.0 ± 12.2 |
| Office MAP (mmHg) | 748 | 99.0 ± 12.5 |
| Pulse rate | 520 | 79.2 ± 13.2 |
| Home SBP/DBP (mmHg) | 546 | 126.8 ± 10.3/ 75.3 ± 9.1 |
| Home MAP (mmHg) | 546 | 92.5 ± 8.2 |
| eGFR (mL/min/1.73 m2) | 565 | 66.9 ± 17.8 |
| HbA1c(mmol/mol (%)) | 546 | 48.1 ± 10.1 (6.5 ± 0.9) |
| Urine albumin-to creatinine ratio (mg/gCr) | 391 | 9.5 [5.4, 26.1] |
| Urine protein (g/gCr) | 79 | 0.16 [0.05, 0.39] |
| Estimated Sodium intake (g/day) | 503 | 8.8 [7.2, 10.4] |
| NT proBNP | 178 | 91.0 [40.5, 193.0] |
| Antihypertensive agents | ||
| ARB | 308 (51%) | |
| ACEI | 40 (7%) | |
| Ca channel blocker | 297 (49%) | |
| β blocker | 84 (14%) | |
| Thiazide | 22 (4%) | |
| Mineralocorticoid receptor blocker | 45 (7%) | |
| Loop diuretic | 9 (2%) | |
| hypoglycemic agents | ||
| DPP4 inhibitor | 150 (25%) | |
| Metformin | 97 (16%) | |
| SGLT2 inhibitor | 68 (11%) | |
| Insulin | 51 (8%) | |
| Sulphonyl urea | 64 (11%) | |
| GLP1 receptor agonist | 20 (3%) | |
| Pioglitazone | 34 (6%) | |
| `αGlucosidase inhibitor | 70 (12%) | |
| Glinide | 32 (5%) | |
| Others | ||
| Statin | 439 (72%) | |
| Ezetimibe | 92 (15%) | |
| Fibrate | 12 (2%) | |
| Antiplatelet | 126 (21%) | |
| EPA | 34 (6%) | |
| Anticoagulant | 22 (4%) | |
Data shown are mean ± standard deviation, median [lower quartile, upper quartile], or numbers (%).
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, COVID-19 corona virus disease 2019, BMI body mass index, BW body weight, DBP diastolic blood pressure, DPP4 dipeptidyl peptidase-4, EPA eicosapentaenoic acid, eGFR estimated glomerular filtration rate, GLP1 glucagon-like peptide 1, HbA hemoglobin A1c, MAP mean arterial pressure, NT proBNP N-terminal pro-brain natriuretic peptide, SBP systolic blood pressure, SGLT2 sodium-glucose co-transporter 2.
The comparison of office BP and home BP. a) Comparison between from January to March 2020 and during the state of emergency in 748 patients. b) Comparison between from April to June 2019, from January to March 2020, and during the state of emergency in 567 patients.
| Jan–Mar in 2020 | During the state of emergency | ||
|---|---|---|---|
| a) BP | |||
| In office ( | |||
| SBP (mmHg) | 136.5 ± 17.5 | 138.6 ± 18.6 | <0.001a |
| DBP (mmHg) | 78.2 ± 12.0 | 79.0 ± 12.2 | 0.03a |
| MAP (mmHg) | 97.6 ± 12.0 | 98.9 ± 12.5 | 0.002 |
| The achievement rate of target BP ( | 207 (29%) | 202 (28%) | 0.77b |
| At home ( | |||
| SBP (mmHg) | 128.2 ± 10.3 | 126.9 ± 10.2 | <0.001a |
| DBP (mmHg) | 75.8 ± 8.8 | 75.2 ± 9.0 | 0.01a |
| MAP (mmHg) | 93.3 ± 7.9 | 92.5 ± 8.1 | 0.001 |
| The achievement rate of target BP ( | 123 (24%) | 160 (31%) | <0.001b |
| b) BP distribution | |||
| Controlled | 71 (13%) | 72 (13%) | <0.001c |
| White-coat | 70 (13%) | 91 (17%) | |
| Masked | 83 (16%) | 67 (13%) | |
| Sustained | 313 (58%) | 307 (57%) | |
Data shown are mean ± standard deviation, or numbers (%).
Among patients with diabetes mellitus, cerebro- or cardio-vascular disease, chronic kidney disease with proteinuria, or under 75 years old, each group were identified as controlled hypertension group, office BP < 130/80 and at home BP < 125/75 mmHg; masked hypertension group, office BP < 130/80 and home BP ≥ 125/75 mmHg; white coat hypertension group, office BP ≧ 130/80 and home BP < 125/75 mmHg; and sustained hypertension group, office BP ≥ 130/80 and home BP ≥ 125/75 mmHg. Among the rest patients other than described above, 10 mmHg was added to the BP thresholds in office and at home. These thresholds were considered as the level of the target BP.
ANOVA analysis of variance, DBP diastolic blood pressure, MAP mean arterial pressure, SBP systolic blood pressure.
aPaired t-test.
bMcNemar’s test.
cChi-square test in Table 2a.
dOne-way repeated ANOVA.
eComparison between from April to June 2019 and during the state of emergency
fComparison between from January to March 2020 and during the state of emergency
gCochran Q test in Table 2b.
Comparisons of other clinical findings before and after the state of emergency.
| Analyzed cases | Before the state of emergency | During or after the state of emergency | ||
|---|---|---|---|---|
| BW (kg) | 690 | 64.1 ± 12.7 | 64.0 ± 12.8 | 0.09 |
| Pulse rate (counts/min) | 520 | 79.1 ± 13.2 | 79.2 ± 13.2 | 0.80 |
| eGFR (mL/min/m2) | 584 | 68.3 ± 18.1 | 67.3 ± 18.2 | 0.003 |
| HbA1c (mmol/mol(%)) | 536 | 47.9 ± 10.5 (6.5 ± 1.0) | 48.2 ± 10.1 (6.6 ± 0.9) | 0.12 |
| Logarithmic value of urine albumin to creatinine ratio (mg/gCr) | 393 | 2.56 ± 1.35 | 2.59 ± 1.32 | 0.40 |
| Urine protein (g/gCr) | 72 | 0.37 ± 0.66 | 0.38 ± 0.86 | 0.87 |
| Logarithmic value of NT-proBNP | 175 | 4.58 ± 1.13 | 4.69 ± 1.14 | 0.01 |
| Estimated salt intake (g/day) | 469 | 9.1 ± 2.0 | 8.9 ± 2.5 | 0.09 |
Data shown are mean ± standard deviation.
BW body weight, eGFR estimated glomerular filtration rate, HbA hemoglobin A1c, NT-proBNP N-terminal pro-brain natriuretic peptide.
Questions related to the change in stress after the state of emergency
| Q1. Do you worry about adverse effects of hypertension as a contributing condition to the severity and poor prognosis of COVID-19? | ||||||
| No, never | Yes, a little | neither yes or no | Yes, moderately | Yes, strongly | No answer | |
| 23 (3%) | 214 (29%) | 37 (5%) | 253 (34%) | 182 (24%) | 39 (5%) | |
| Q2. How did the stress in your daily life change after the declaration of emergency due to the rapid spread of COVID-19? | ||||||
| Much decreased | A little decreased | Usual | A little increased | Much increased | No answer | |
| 13 (2%) | 28 (4%) | 313 (42%) | 298 (40%) | 87 (11%) | 9 (1%) | |
| Q3. How did your lifestyle change after the declaration of emergency due to the rapid spread of COVID-19? | ||||||
| Much improved | A little improved | Usual | A little worsened | Much worsened | No answer | |
| Dietary intake | 21 (3%) | 68 (10%) | 533 (70%) | 119 (16%) | 5 (1%) | 2 (0%) |
| Salt intake | 18 (3%) | 82 (11%) | 599 (80%) | 45 (6%) | 1 (0%) | 3 (0%) |
| The frequency of dinner or lunch at home | 81 (11%) | 92 (12%) | 554 (74%) | 15 (2%) | 2 (0%) | 4 (1%) |
| Amount of exercise | 26 (4%) | 69 (9%) | 361 (48%) | 209 (28%) | 80 (11%) | 3 (0%) |
| Quality of sleep | 20 (3%) | 49 (7%) | 572 (76%) | 94 (13%) | 9 (1%) | 4 (0%) |
| Amount of alcohol intake | 59 (8%) | 46 (6%) | 597 (80%) | 28 (4%) | 4 (0%) | 14 (2%) |
| Adherence to taking medications | 17 (2%) | 12 (2%) | 690 (92%) | 19 (3%) | 2 (0%) | 8 (1%) |
| The stress score for each answer | −2 | −1 | 0 | +1 | +2 | 0 |
COVID-19 corona virus disease 2019.
Comparisons between two groups divided by 3 of the total stress score before and after the state of emergency.
| Jun–Mar 2020 | During the state of emergency | |||||
|---|---|---|---|---|---|---|
| The total stress score | <3 | ≧3 | <3 | ≧3 | ||
| Age | 66.7 ± 12.5 | 67.3 ± 12.1 | 0.59 | |||
| Gender (Male) | 318 (63%) | 73 (44%) | <0.001 | |||
| Office SBP (mmHg) | 137.5 ± 18.1 | 135.3 ± 16.1 | 0.16 | 138.7 ± 18.5 | 140.1 ± 19.4 | 0.04 |
| Office DBP (mmHg) | 78.4 ± 12.2 | 78.6 ± 11.7 | 0.88 | 79.1 ± 11.8 | 80.4 ± 13.1 | 0.13 |
| Office MAP (mmHg) | 98.1 ± 12.3 | 97.5 ± 11.4 | 0.57 | 99.9 ± 12.3 | 100.3 ± 13.4 | 0.048 |
| Home SBP (mmHg) | 127.9 ± 10.1 | 128.6 ± 11.0 | 0.48 | 126.3 ± 9.9 | 127.6 ± 11.3 | 0.18 |
| Home DBP (mmHg) | 76.1 ± 9.1 | 75.9 ± 8.7 | 0.85 | 75.1 ± 9.1 | 76.2 ± 9.6 | 0.01 |
| Home MAP (mmHg) | 93.3 ± 8.2 | 93.5 ± 7.9 | 0.88 | 92.2 ± 8.0 | 93.3 ± 9.1 | 0.02 |
| BW (kg) | 64.5 ± 12.4 | 64.3 ± 14.1 | 0.87 | 64.4 ± 12.5 | 64.4 ± 14.1 | 0.70 |
| eGFR (mL/min/1.73 m2) | 69.2 ± 18.0 | 66.1 ± 17.3 | 0.08 | 67.8 ± 18.0 | 65.7 ± 17.6 | 0.68 |
| HbA1c(mmol/mol (%)) | 47.7 ± 10.8 (6.5 ± 1.0) | 47.6 ± 10.3 (6.5 ± 0.9) | 0.92 | 48.0 ± 10.2 (6.5 ± 0.9) | 47.9 ± 9.9 (6.5 ± 0.9) | 0.89 |
| The logarithmic value of ACR | 2.46 ± 1.36 | 2.45 ± 1.32 | 0.95 | 2.55 ± 1.28 | 2.65 ± 1.34 | 0.12 |
| Estimated salt intake (g/day) | 9.1 ± 2.1 | 9.0 ± 2.0 | 0.70 | 8.9 ± 2.4 | 8.8 ± 2.5 | 0.69 |
| Urine Na/K ratio | 1.62 ± 0.86 | 1.56 ± 0.80 | 0.55 | 1.57 ± 1.11 | 1.63 ± 1.17 | 0.68 |
Data shown are mean ± standard deviation, or numbers (%).
ANCOVA analysis of covariance, ACR urine albumin-to-creatinine ratio, BW body weight, COVID-19 coronavirus disease, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, MAP mean arterial pressure.
aAnswers “Yes, moderately” or “Yes, strongly”.